

CITATION REPORT

List of articles citing

Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future

DOI: 10.2165/00003088-200544040-00003
Clinical Pharmacokinetics, 2005, 44, 367-93.

Source: <https://exaly.com/paper-pdf/39421277/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
176	Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL). <i>Pediatric Blood and Cancer</i> , 2006 , 47, 299-304	3	13
175	Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. <i>Blood</i> , 2007 , 109, 2744-50	2.2	124
174	Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children@ Oncology Group. <i>Blood</i> , 2007 , 110, 1429-38	2.2	41
173	Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. 2007 , 29, 239-47		25
172	L-Asparaginase from <i>Erwinia Chrysanthemi</i> 3937: cloning, expression and characterization. 2007 , 127, 657-69		103
171	FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). 2007 , 12, 991-8		209
170	L-asparaginase: a promising chemotherapeutic agent. 2007 , 27, 45-62		126
169	Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. 2007 , 110, 103-11		518
168	Modification of recombinant asparaginase from <i>Erwinia carotovora</i> with polyethylene glycol 5000. 2007 , 1, 230-232		3
167	Anti-cancer PEG-enzymes: 30 years old, but still a current approach. 2008 , 60, 69-78		115
166	Octreotide prevents L-asparaginase-induced pancreatic injury in rats. 2008 , 36, 172-80		13
165	Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 487-513	6.2	30
164	The treatment of adults with acute lymphoblastic leukemia. 2008 , 381-9		25
163	Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. <i>Blood</i> , 2008 , 112, 4832-8	2.2	59
162	A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. 2009 , 119, 1964-73		61
161	Pegaspargase: where do we stand?. 2009 , 9, 111-9		45
160	The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2009 , 90, 347-352	2.3	9

159	Optimal management of adults with ALL. <i>British Journal of Haematology</i> , 2009 , 144, 468-83	4.5	40
158	Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. 2009 , 86, 651-8		60
157	Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. 2010 , 32, 554-63		73
156	Glutamine addiction: a new therapeutic target in cancer. 2010 , 35, 427-33		1127
155	A population pharmacokinetic model for pegylated-asparaginase in children. <i>British Journal of Haematology</i> , 2010 , 148, 119-25	4.5	27
154	[Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia]. 2010 , 97, 1105-17		8
153	Peg-asparaginase for acute lymphoblastic leukemia. 2010 , 10, 833-9		43
152	Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2237-53	1.9	160
151	Current therapeutic strategies in adult acute lymphoblastic leukemia. 2011 , 25, 1255-79, viii		16
150	Asparaginase revisited. <i>Leukemia and Lymphoma</i> , 2011 , 52, 168-78	1.9	73
149	Metabolic alterations in cancer cells and therapeutic implications. 2011 , 30, 508-25		63
148	Asparaginases: a successful class of drugs against leukemias and lymphomas. 2011 , 33, 573-9		16
147	Proteins from Erwinia asparaginase Erwinase \square and E. coli asparaginase 2 MEDAC \square for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear. 2011 , 32, 1824-8		8
146	Bacterial Asparaginase: A Potential Antineoplastic Agent for Treatment of Acute Lymphoblastic Leukemia. 2012 , 225-244		1
145	Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer. 2012 , 502, 291-319		30
144	Asparaginase-associated pancreatitis in children. <i>British Journal of Haematology</i> , 2012 , 159, 18-27	4.5	71
143	Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1. 2012 , 72, 4526-36		40
142	De novo engineering of a human cystathionine- β -lyase for systemic (L)-Methionine depletion cancer therapy. 2012 , 7, 1822-9		24

141	Erwinia asparaginase in pediatric acute lymphoblastic leukemia. 2012 , 12, 1407-14		19
140	Cancer metabolism: current perspectives and future directions. 2012 , 3, e248		282
139	L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels. 2012 , 12, 49-55		9
138	Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin-Frankfurt-Münster-based induction therapy for childhood acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1682-7	1.9	6
137	Chemotherapy-induced hepatotoxicity. 2013 , 17, 671-86, ix-x		28
136	Therapeutic strategies impacting cancer cell glutamine metabolism. 2013 , 5, 1685-700		82
135	Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. <i>Blood</i> , 2013 , 122, 507-14	2.2	54
134	Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic Acids, and Mammalian Cells. 2013 , 677-690		1
133	Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. 2013 , 31, 1202-10		221
132	L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers. 2013 , 59, 167-75		24
131	Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing properties. 2014 , 289, 33175-86		33
130	Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2014 , 166, 213-20	4.5	19
129	Asparaginase in acute lymphoblastic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14 Suppl, S14-7	2	32
128	Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. 2014 , 32, 795-805		19
127	Cell-penetrating peptides mediated encapsulation of protein therapeutics into intact red blood cells and its application. 2014 , 176, 123-132		88
126	Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. 2014 , 32, 3874-82		66
125	Crystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding site. 2014 , 281, 4097-111		18
124	Structural and kinetic characterization of guinea pig L-asparaginase type III. 2014 , 53, 2318-28		16

123	Asparaginase in the treatment of non-ALL hematologic malignancies. 2014 , 73, 875-83		23
122	Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. 2014 , 73, 1307-13		18
121	Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. 2014 , 12, 694-702		48
120	How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. 2014 , 10, 2615-27		31
119	A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. <i>Blood</i> , 2014 , 124, 3027-9	2.2	10
118	Clinical application of asparaginase activity levels following treatment with pegaspargase. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1102-5	3	29
117	Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. 2015 , 52, 165-71		40
116	Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo. 2015 , 22, 629-39		40
115	Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase. 2015 , 4, 118-28		34
114	Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. <i>Clinical Cancer Research</i> , 2015 , 21, 680-6	12.9	69
113	Asparagine synthetase polymorphisms and toxicity and efficacy of asparaginases. <i>Clinical Cancer Research</i> , 2015 , 21, 230-2	12.9	1
112	Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2273-80	1.9	79
111	Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. <i>Blood Reviews</i> , 2015 , 29, 243-9	11.1	36
110	Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. 2015 , 39, 757-62		61
109	Identification of functional regions in the Rhodospirillum rubrum L-asparaginase by site-directed mutagenesis. 2015 , 57, 251-64		25
108	Cloning, expression and characterization of L-asparaginase from Pseudomonas fluorescens for large scale production in E. coli BL21. 2015 , 5, 975-981		22
107	Catalytic Role of the Substrate Defines Specificity of Therapeutic L-Asparaginase. 2015 , 427, 2867-85		21
106	The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience. 2016 , 38, e16-20		11

105	Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia. 2016 , 12, 1609-21		18
104	Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation. 2016 , 244, 184-193		319
103	Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study. <i>Scientific Reports</i> , 2016 , 6, 39463	4.9	6
102	Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia. 2016 , 5, 11-25		14
101	Glutaminolysis and carcinogenesis of oral squamous cell carcinoma. 2016 , 273, 495-503		18
100	Recent developments in L-asparaginase discovery and its potential as anticancer agent. 2016 , 100, 1-10		118
99	Asparaginase <i>Erwinia chrysanthemi</i> as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase. 2016 , 9, 227-34		10
98	Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2016 , 22, 354-6	1.7	2
97	Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. 2016 , 128, 57-66		17
96	Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 748-57	1.9	108
95	Therapeutic l-asparaginase: upstream, downstream and beyond. 2017 , 37, 82-99		77
94	Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study. 2017 , 39, 202-209		7
93	In search of druggable targets for GBM amino acid metabolism. <i>BMC Cancer</i> , 2017 , 17, 162	4.8	45
92	Plasma asparaginase activity, asparagine concentration, and toxicity after administration of <i>Erwinia</i> asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26475	3	1
91	Reactions related to asparaginase infusion in a 10-year retrospective cohort. 2017 , 39, 337-342		8
90	A protease-resistant <i>Escherichia coli</i> asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro. <i>Scientific Reports</i> , 2017 , 7, 14479	4.9	22
89	Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?. 2017 , 21, E248-E259		6
88	Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy. 2017 , 1, 114-130		8

87	Acid-suppressing Drugs and a Low 1 Level of Antithrombin as Risk Factors for L-Asparaginase-associated Pancreatitis: A Case-control Study in the Japan Association of Childhood Leukemia Study (JACLS). 2018 , 40, 374-378		1
86	Retrospective post-marketing study on the use of bio-similar pegaspargase among acute lymphoblastic leukemia patients in India. 2018 , 3, 9-12		0
85	Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27065	3	4
84	Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. <i>Journal of Oncology Pharmacy Practice</i> , 2018 , 24, 299-308	1.7	25
83	Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1797-1806	1.9	49
82	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children@ Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26873	3	37
81	Expression and characterization of recombinant l-asparaginase from <i>Pseudomonas fluorescens</i> . <i>Protein Expression and Purification</i> , 2018 , 143, 83-91	2	19
80	Personalized nanomedicine: a rapid, sensitive, and selective UV-vis spectrophotometry method for the quantification of nanostructured PEG-asparaginase activity in children@ plasma. <i>International Journal of Nanomedicine</i> , 2018 , 13, 6337-6344	7.3	4
79	PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. <i>BMC Cancer</i> , 2018 , 18, 910	4.8	4
78	Cancer Metabolism: Current Understanding and Therapies. 2018 , 118, 6893-6923		89
77	Optimization of a Precolumn OPA Derivatization HPLC Assay for Monitoring of l-Asparagine Depletion in Serum during l-Asparaginase Therapy. 2018 , 56, 794-801		7
76	Pharmacodynamic monitoring using biomarkers to individualize pharmacotherapy. <i>Biomarkers in Medicine</i> , 2019 , 13, 393-408	2.3	0
75	Amino acid metabolism in hematologic malignancies and the era of targeted therapy. <i>Blood</i> , 2019 , 134, 1014-1023	2.2	45
74	Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study. <i>International Journal of Hematology</i> , 2019 , 110, 458-465	2.3	1
73	SLC1A3 contributes to L-asparaginase resistance in solid tumors. <i>EMBO Journal</i> , 2019 , 38, e102147	13	25
72	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children@ Oncology Group AALL07P4. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1740-1748	1.9	18
71	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. <i>Haematologica</i> , 2019 , 104, 1812-1821	6.6	19
70	Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1587-1592	6.1	22

69	Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27797	3	29
68	Expression, purification, and characterization of asparaginase II from <i>Saccharomyces cerevisiae</i> in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 2019 , 159, 21-26	2	4
67	A structural in silico analysis of the immunogenicity of L-asparaginase from <i>Escherichia coli</i> and <i>Erwinia carotovora</i> . <i>Biologicals</i> , 2019 , 59, 47-55	1.8	11
66	The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. <i>Health Economics Review</i> , 2019 , 9, 40	2	1
65	Discovery and development of small molecule modulators targeting glutamine metabolism. <i>European Journal of Medicinal Chemistry</i> , 2019 , 163, 215-242	6.8	20
64	Glutamine Addiction and Therapeutic Strategies in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	40
63	Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 74-92	1.7	9
62	In silico analysis of codon usage and rare codon clusters in the halophilic bacteria L-asparaginase. <i>Biologia (Poland)</i> , 2020 , 75, 151-160	1.5	1
61	Asparaginase activities during intensified treatment with pegylated asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 138-145	1.9	14
60	Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 614-622	1.9	15
59	Asparaginase: an old drug with new questions. <i>Hematology, Transfusion and Cell Therapy</i> , 2020 , 42, 275-288		8
58	Transformation of the L-Asparaginase II Gene to Potato Hairy Roots for Production of Recombinant Protein. <i>Journal of Crop Science and Biotechnology</i> , 2020 , 23, 81-88	1.2	5
57	Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28063	3	2
56	FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults. <i>Clinical Cancer Research</i> , 2020 , 26, 328-331	12.9	10
55	National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. <i>BMC Cancer</i> , 2020 , 20, 956	4.8	
54	Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia. <i>JCO Global Oncology</i> , 2020 , 6, 1009-1016	3.7	2
53	Glycosylation of Erwinase results in active protein less recognized by antibodies. <i>Biochemical Engineering Journal</i> , 2020 , 163, 107750	4.2	3
52	Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. <i>Molecules</i> , 2020 , 25,	4.8	19

51	Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients. <i>Technology in Cancer Research and Treatment</i> , 2020 , 19, 1533033820980113	2.7	2
50	Development and Validation of a Hydrophilic Interaction Liquid Chromatography Tandem Mass Spectrometry Method for the Determination of Asparagine in Human Serum. <i>International Journal of Analytical Chemistry</i> , 2020 , 2020, 6980392	1.4	
49	Immunogenicity assessment of fungal l-asparaginases: an in silico approach. <i>SN Applied Sciences</i> , 2020 , 2, 1	1.8	2
48	Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review. <i>Seminars in Cancer Biology</i> , 2020 ,	12.7	28
47	Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium. <i>British Journal of Haematology</i> , 2020 , 190, 105-114	4.5	6
46	Immunogenicity of Polyethylene Glycol Based Nanomedicines: Mechanisms, Clinical Implications and Systematic Approach. <i>Advanced Therapeutics</i> , 2020 , 3, 1900170	4.9	20
45	A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications. <i>Biotechnology and Applied Biochemistry</i> , 2020 , 67, 619-647	2.8	29
44	Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. <i>Blood Reviews</i> , 2020 , 43, 100651	11.1	15
43	Diseases & Disorders Therapies Targeting Glutamine Addiction in Cancer. 2021 , 452-461		1
42	Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021 , 11, 25-40	2.6	5
41	PEG-asparaginase treatment for acute lymphoblastic leukaemia in children: a network meta-analysis. <i>The Cochrane Library</i> , 2021 , 2021,	5.2	
40	Circumventing the side effects of L-asparaginase. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 139, 111616	7.5	6
39	Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications. <i>Current Medicinal Chemistry</i> , 2021 ,	4.3	3
38	L-Asparaginase-Based Biosensors. <i>Encyclopedia</i> , 2021 , 1, 848-858		1
37	L-asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study. <i>Cancer Reports</i> , 2021 , e1533	1.5	
36	Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells. <i>Cancer Cell International</i> , 2021 , 21, 479	6.4	4
35	Revealing Escherichia coli type II L-asparaginase active site flexible loop in its open, ligand-free conformation. <i>Scientific Reports</i> , 2021 , 11, 18885	4.9	1
34	Asparaginase: Understanding and Overcoming Toxicities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, S90-S94	2	

33	Molecular dynamics simulations of human L-asparaginase1: Insights into structural determinants of enzymatic activity. <i>Journal of Molecular Graphics and Modelling</i> , 2021 , 109, 108007	2.8	0
32	Enzymes in Metabolic Anticancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1148, 173-199	3.6	11
31	Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. <i>PLoS ONE</i> , 2012 , 7, e33894	3.7	46
30	Recombinant L-Asparaginase from <i>Zymomonas mobilis</i> : A Potential New Antileukemic Agent Produced in <i>Escherichia coli</i> . <i>PLoS ONE</i> , 2016 , 11, e0156692	3.7	17
29	Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015 , 6, 43048-64	3.3	34
28	Amino Acid Degrading Enzymes and their Application in Cancer Therapy. <i>Current Medicinal Chemistry</i> , 2019 , 26, 446-464	4.3	14
27	Insights into the Microbial L-Asparaginases: from Production to Practical Applications. <i>Current Protein and Peptide Science</i> , 2019 , 20, 452-464	2.8	11
26	Chemical metabolic inhibitors for the treatment of blood-borne cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014 , 14, 223-32	2.2	22
25	Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia. <i>Haematologica</i> , 2020 , Online ahead of print,	6.6	11
24	Cloning, Purification, Characterization and Immobilization of L-asparaginase II from <i>E. coli</i> W3110. <i>Asian Journal of Biochemistry</i> , 2008 , 3, 337-350	0.1	19
23	L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2016 , 7, 62-71	0.2	116
22	Purification and Biochemical Characterization of Native and Pegylated Form of L-Asparaginase from <i>Aspergillus terreus</i> and Evaluation of Its Antiproliferative Activity. <i>Advances in Microbiology</i> , 2012 , 02, 138-145	0.6	25
21	The effect of dietary asparagine supplementation on energy metabolism in liver of weaning pigs when challenged with lipopolysaccharide. <i>Asian-Australasian Journal of Animal Sciences</i> , 2018 , 31, 548-555	2.4	5
20	Recent new drug approvals. Part 1: drugs with pediatric indications. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2012 , 17, 329-39	1.6	2
19	Nutriments et cancer : alli� ou ennemis ?. <i>Cahiers De Nutrition Et De Dietetique</i> , 2020 , 55, 276-294	0.2	
18	Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. <i>International Journal of Nanomedicine</i> , 2006 , 1, 241-54	7.3	83
17	First-line treatment of acute lymphoblastic leukemia with pegasparaginase. <i>Biologics: Targets and Therapy</i> , 2009 , 3, 359-68	4.4	18
16	Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012. <i>Canadian Veterinary Journal</i> , 2016 , 57, 176-82	0.5	5

15	Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia.. <i>Blood Reviews</i> , 2021 , 100908	11.1	1
14	A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity. <i>Cancers</i> , 2021 , 13,	6.6	0
13	Delivery strategies in treatments of leukemia.. <i>Chemical Society Reviews</i> , 2022 ,	58.5	2
12	Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy.. <i>Cancers</i> , 2022 , 14,	6.6	3
11	Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer. <i>Cancers</i> , 2022 , 14, 2491	6.6	1
10	Pegylated asparaginase in feline high-grade lymphoma: clinical results of single injection and continued incorporation into a modified COP regimen. <i>Journal of Feline Medicine and Surgery</i> , 1098612X2211015	2.5	1
9	Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs: A multi-phase preclinical study. <i>Veterinary Journal</i> , 2022 , 286, 105854	2.5	
8	SOHO State of the Art Updates and Next Questions Asparaginase Understanding and Overcoming Toxicities in Adults with ALL. 2022 ,		1
7	Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic Acids, and Mammalian Cells in Safety Pharmacology. 2022 , 1-27		0
6	Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece. 2022 , 42, 999-1008		0
5	A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL).		0
4	Thermostability Improvement of L-Asparaginase from <i>Acinetobacter soli</i> via Consensus-Designed Cysteine Residue Substitution. 2022 , 27, 6670		0
3	Identification of an Amino Acid Metabolism-Related Gene Signature for Predicting Prognosis in Lung Adenocarcinoma. 2022 , 13, 2295		0
2	A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native <i>E. coli</i> asparaginase in children with acute lymphoblastic leukemia. 107815522311645		0
1	L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase. 2023 , 426, 113568		0